Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.The kidney disease company met with the U.S. Food and Drug Administration (FDA) and has not reached an agreement on a path forward for the VALOR trial design, which involves the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease (CKD) who are not on dialysis.Also Read: CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week HighAs a result, Akebia does not plan to initiate VALO ...